Mumbai: Sun Pharma / Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA | BSE: 524715), India’s largest pharmaceutical company and a global leader in specialty generics, has announced the successful completion of its acquisition of Checkpoint Therapeutics, Inc., a U.S.-based immunotherapy and oncology-focused biopharma company.
This strategic acquisition adds UNLOXCYT (cosibelimab) – the first and only FDA-approved anti-PD-L1 immunotherapy for the treatment of advanced cutaneous squamous cell carcinoma (cSCC) – to Sun Pharma’s specialty portfolio.
The deal further strengthens the company’s presence in the high-growth onco-dermatology segment.
Addressing a Critical Cancer Burden
Cutaneous squamous cell carcinoma is the second most common skin cancer in the United States, affecting approximately 1.8 million people annually, according to the Skin Cancer Foundation.
While the majority of cSCC cases can be treated surgically, an estimated 40,000 cases become advanced, leading to 15,000 annual deaths.
Strategic Milestone for Sun Pharma
“This acquisition exemplifies our company’s strategic vision to expand our innovative therapies portfolio and address unmet clinical needs,” said Dilip Shanghvi, Chairman and Managing Director of Sun Pharma. “By adding UNLOXCYT, we are reinforcing our position in the onco-dermatology space, helping patients access life-saving treatments while enhancing our global specialty product offerings.”
The company will leverage its global commercial infrastructure, particularly in oncology and dermatology, to accelerate market access for UNLOXCYT and maximize its impact in the U.S. and other key international markets.
Deal Structure and Financial Terms
Under the terms of the agreement, Sun Pharmaceutical Industries has acquired all outstanding shares of Checkpoint for $4.10 per share in cash, along with a contingent value right (CVR) of up to $0.70 per share, payable if certain regulatory and commercial milestones are achieved.
Expanding Specialty Focus
Sun Pharma’s global specialty business, which now accounts for over 18% of its total revenues, continues to see rapid expansion. The company is especially active in dermatology, ophthalmology, and oncology, supported by a robust pipeline and deep R&D investments.
About Sun Pharmaceutical Industries Ltd
Sun Pharma is a leading global pharmaceutical company with operations in over 100 countries. With a strong presence in specialty, generics, and consumer healthcare, it operates manufacturing facilities across six continents. Its differentiated product portfolio and vertically integrated operations make it one of the most trusted pharmaceutical brands worldwide.
